NCT03016377 2025-10-27
Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL
UNC Lineberger Comprehensive Cancer Center
Phase 1/2 Active not recruiting
Clinical Trials
10 trialsNCT03207854 2025-07-11
Collection of Immunology Specimens From Patients With Cancer or Blood Disorders, and Healthy Volunteers
University of Southern California
Recruiting
NCT05963217 2025-07-02
Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL
University Health Network, Toronto
Phase 1 Recruiting
NCT05969821 2025-06-12
CHIS
Assistance Publique - HĂ´pitaux de Paris
Not yet recruiting
NCT03594162 2021-12-03
Compassionate Use of CAR T Cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch
UNC Lineberger Comprehensive Cancer Center
No longer available
NCT01200017 2021-05-27
Expanded Access Protocol (EAP) Using the CliniMACS® Device for Pediatric Haplocompatible Donor Stem Cell Transplant
University of California, San Francisco
No longer available
NCT02799147 2020-11-23
GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia
St. Petersburg State Pavlov Medical University
Phase 1/2 Completed
NCT02670564 2019-04-16
ALL SCTped FORUM - Pharmacogenomic Study (add-on Study)
Swiss Pediatric Oncology Group
Phase 4 Recruiting
NCT02627573 2019-04-05
Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT
St. Petersburg State Pavlov Medical University
Phase 2 Terminated
NCT02294552 2018-01-16
Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT
St. Petersburg State Pavlov Medical University
Phase 2 Completed